| Clene is a clinical-stage pharmaceutical company focusing on the discovery, development, and commercialization of clean-surfaced nanotechnology therapeutics. Co. is focused on addressing the unmet medical needs in two areas: first, those related to central nervous system disorders including Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson's Disease; and second, those related to COVID-19, an infectious viral respiratory disease with serious and sometimes fatal co-morbidities. In addition to the development of clean-surfaced nanocrystals, Co.'s electro-crystal-chemistry platform can produce ionic solutions of various transition elements including silver, zinc, and others. The CLNN YTD return is shown above.
The YTD Return on the CLNN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether CLNN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CLNN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.